Eisai Co Ltd - ADR

Eisai Co Ltd - ADR

ESALY

Get informed when a big investor buys or sells

+ Follow
Market Cap$17.64B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Eisai Co Ltd - ADREisai Co Ltd - ADR28.54.1%3%-0.2

Share Statistics

Market cap$17.64 Billion
Enterprise Value$-100,246,837,944.00
Dividend Yield$19.23 (4.10%)
Earnings per Share$159.44
Beta0
Outstanding Shares286,794,957

Return

Return on Equity3.50%ROE
Return on Assets2.16%
Return on Invested Capital-0.17%

Valuation & Multiples

P/E Ratio28.54P/E Ratio
PEG-94.9PEG
Price to Sales0.02Price to Sales
Price to Book Ratio0.02Price to Book Ratio
Enterprise Value to Revenue-0.14
Enterprise Value to EBIT64.47
Enterprise Value to Net Income-4
Total Debt to Enterprise-1.5
Debt to Equity0.19Debt to Equity

Revenue Sources

No data

Insider Trades

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Eisai Co Ltd

CEO: Haruo Naito

Relevant Senate Committees

Finance

Controls taxation, trade, and entitlement spending (like Medicare and Medicaid), directly impacting pharmaceutical company profitability through tax policy, market access, and drug reimbursement rates.

Appropriations

Directly controls the allocation of federal funds to agencies critical for the pharmaceutical industry, such as the NIH (research) and the FDA (regulation), and determines budgets for government drug procurement.

Health, Education, Labor, and Pensions

Directly regulates the FDA (responsible for drug approval and safety) and oversees the NIH (major funder of biomedical research), making it a primary legislative body for the pharmaceutical industry.

Judiciary

Has direct oversight over intellectual property (patents), which is fundamental to the pharmaceutical business model, and antitrust enforcement, which impacts mergers and acquisitions within the industry.